Skip to main content
. 2022 May 25;28(7):1461–1467. doi: 10.1038/s41591-022-01840-0

Extended Data Fig. 4. Risk and 6-month excess burden of post-acute sequelae in people with breakthrough SARS-CoV-2 infection by immunocompromised status.

Extended Data Fig. 4

(A) Breakthrough SARS-CoV-2 infection compared to the contemporary control (n=4,983,491) in non-immunocompromised (n=27,431) and immunocompromised (n=6,509) individuals. (B) A within breakthrough SARS-CoV-2 infection comparison between immunocompromised (n=6,509) and non-immunocompromised (n=27,431) individuals. Incident outcomes were assessed from 30 days after the positive SARS-CoV-2 test to end of follow-up. Adjusted hazard ratios (dots) and 95% confidence intervals (error bars) are presented, as are estimated excess burden (bars) and 95% confidence intervals (error bars). Burdens are presented per 1000 persons at 6 months of follow-up.